Squarepoint’s Grace Therapeutics GRCE Stock Holding History

Squarepoint’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,969	Closed	-$53K	–	3526
2021 Q2	$53K	Buy	1,969 +1,569	+392%	+$38.2K	﹤0.01%	3101
2021 Q1	$12K	Buy	+400	New	+$13.9K	﹤0.01%	3036

Other funds holding GRCE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Squarepoint's GRCE Position: Q3 2021 in Review

Squarepoint sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 1,969 shares — an estimated $53K sold.

Squarepoint first reported a position in GRCE in Q1 2021 and held it in 2 quarters. The position peaked at $53K in Q2 2021. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

Squarepoint reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
Squarepoint sold 1,969 Grace Therapeutics shares in Q3 2021, an estimated $53K.
Squarepoint first reported a position in Grace Therapeutics in Q1 2021 and held it in 2 quarters.
Squarepoint's Grace Therapeutics position peaked at $53K in Q2 2021.
17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.